NCT00952913已完成1 期
A Study to Examine The Potential Effect Of Lansoprazole On The Pharmacokinetics Of Bosutinib When Administered Concomitantly To Healthy Subjects
Wyeth is now a wholly owned subsidiary of Pfizer1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2009年8月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Pharmacokinetics as measured by Cmax, AUC, tmax, t1/2
研究概览
简要总结
The purpose of this study is to see if there is an effect on the pharmacokinetics of bosutinib when administered with lansoprazole.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy men and women of nonchildbearing potential, between the ages of 18 to 50 years old.
排除标准
- •Any cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
研究组 & 干预措施
1
Experimental
Bosutinib
干预措施: Bosutinib (Drug)
2
Experimental
bosutinib + lansoprazole
干预措施: Bosutinib (Drug)
2
Experimental
bosutinib + lansoprazole
干预措施: Lansoprazole (Drug)
结局指标
主要结局
Pharmacokinetics as measured by Cmax, AUC, tmax, t1/2
时间窗: 1 month
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Effect of Rifampin on Bosutinib When Both Are Given to Healthy PeopleHealthyNCT00725426Wyeth is now a wholly owned subsidiary of Pfizer24
已完成
1 期
Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy SubjectsLeukemia, Myeloid, ChronicBreast CancerNCT00759837Wyeth is now a wholly owned subsidiary of Pfizer27
已完成
2 期
Bosutinib in Elderly Chronic Myeloid LeukemiaChronic Myeloid LeukemiaNCT02810990Gruppo Italiano Malattie EMatologiche dell'Adulto65
已完成
不适用
A Study To Describe The Real World Use Of Bosutinib In The UK And NetherlandsChronic Myeloid LeukaemiaNCT02546375Pfizer87
已完成
1 期
Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CMLB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveBlasts More Than 5 Percent of Bone Marrow Nucleated CellsCD22 PositivePhiladelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRefractory Chronic Myelogenous Leukemia, BCR-ABL1 PositiveNCT02311998M.D. Anderson Cancer Center22